USD10
NXTC Shares
About NextCureNextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

USD10
NXTC Shares
About NextCureNextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Stats

TRADING WINDOW

Closed

OPENS AT

Not enough data

MARKET CAP

$29.65M

OPEN PRICE

$5.27

LOW (1Y)

$1.55

HIGH (1Y)

$15.74

LOW (24H)

$5.15

HIGH (24H)

$5.91

VOLUME (24H)

$315.88K

68.56%

Price history

Time
Price
Change
Today
$5.27
22.92%
1 Day
$5.42
19.52%
1 Week
$4.21
53.87%
1 Month
$1.74
272.30%
1 Year
$4.80
34.96%

Discover more

Legal
All securities and investments are offered by Coinbase Capital Markets Corp, member FINRA/SIPC. Securities services offered by Coinbase Capital Markets Corp are separate from digital asset services provided by Coinbase Inc., and any affiliates or crypto asset services provided under MiCA by Coinbase Luxembourg S.A. SIPC does not apply to digital assets or cash held in your Coinbase Inc. account. Additional information about your broker, Coinbase Capital Markets Corp, can be found on FINRA’s BrokerCheck. Execution, clearing and custody of all securities are provided by Apex Clearing Corporation.This page and the content herein is for informational purposes only and does not constitute the provision of investment advice. The customer assumes full responsibility for its trading activity and should consult its advisors for its specific situation. This material is not (i) an offer, or solicitation of an offer, to invest in, or to buy or sell, any interests or shares, or to participate in any investment or trading strategy, (ii) intended to provide accounting, legal, or tax advice, or investment recommendations. The information is believed to be current as of the date indicated and may not be updated or otherwise revised to reflect information that subsequently became available or a change in circumstances after the date of publication. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. Recipients should consult their advisors before making any investment decision.All ticker names are trademarks of their respective holders. Any ticker reference does not imply any affiliation with or endorsement by a third party. Real-time quote and/or trade prices are not sourced from all markets, source: Nasdaq Last Sale. Morningstar data ©2026.